Navigation Links
Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
Date:8/4/2008

Agency Supports Amigal Move to Phase 3; Eligible for Accelerated Approval;

Final Global Regulatory Plan Expected by Year End

CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, announced today that it has successfully completed an End of Phase 2 meeting for Amigal(TM) with the U.S. Food and Drug Administration (FDA). The FDA indicated that the data from the completed Phase 2 clinical studies of Amigal support the start of Phase 3 development and agreed that Amigal meets the criteria to be considered for accelerated approval. The Agency further indicated that it is not opposed to the use of a surrogate primary endpoint, pending further discussion and final agreement on the Phase 3 trial design.

Amicus, along with its partner Shire Human Genetic Therapies, Inc. ("Shire"), is engaged in ongoing discussions with the FDA and the European Medicines Agency (EMEA) regarding plans for a global Phase 3 clinical development program for Amigal. In line with previous guidance, Amicus expects to complete these interactions in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate Phase 3 development of Amigal in the first half of 2009.

"We are very pleased with the outcome of the End of Phase 2 meeting with the FDA," said John F. Crowley, President and CEO of Amicus Therapeutics. "We look forward to continuing our work with the FDA and EMEA to design a global Phase 3 program for Amigal in Fabry disease."

The meeting followed the successful conduct of Phase 2 clinical studies in patients wit
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
2. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
3. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
4. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
5. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
11. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  MedAptus® today announced ... designed to simplify pre-care needs for busy inpatient ... to automatically assign patients to hospitalists or other ... care and other requirements such as ensuring patient ... In ...
(Date:3/30/2015)... CHARLOTTE, N.C. , March 30, 2015 /PRNewswire/ ... today announced a worldwide search for product innovations ... The most promising ideas uncovered during the 8-week ... partners for potential commercialization.  Invention ideas can be ... www.EdisonNationMedical.com/Mobility now through May 28, 2015. ...
(Date:3/30/2015)... International Inc. (OTCQB: NUIN) ("Nutrastar" or the "Company"), a ... including commercially cultivated Cordyceps Militaris ("Cordyceps"), functional health beverages ... for the full year ended December 31, 2014. ... December 31, 2014   , Net ... in full year 2013. , Gross ...
Breaking Medicine Technology:MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 2MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 3Edison Nation Medical Announces Open Innovation Search Focused on Senior Mobility Products 2Edison Nation Medical Announces Open Innovation Search Focused on Senior Mobility Products 3Nutrastar International, Inc. Announces Full Year 2014 Results 2Nutrastar International, Inc. Announces Full Year 2014 Results 3Nutrastar International, Inc. Announces Full Year 2014 Results 4Nutrastar International, Inc. Announces Full Year 2014 Results 5Nutrastar International, Inc. Announces Full Year 2014 Results 6Nutrastar International, Inc. Announces Full Year 2014 Results 7Nutrastar International, Inc. Announces Full Year 2014 Results 8Nutrastar International, Inc. Announces Full Year 2014 Results 9
(Date:3/30/2015)... “ iCareTech ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... expert, conducted the review and shared with viewers how this ... medical and health fields. , Wearable technology has been one ... couple of years. Well, at CES, NewsWatch TV came across ...
(Date:3/30/2015)... Innovaacom, a leading provider of medical education ... is expanding its services into Asia in 2015. Innovaacom’s ... world comes at a time when Asia’s strengthening economy ... healthcare. A rapidly growing aging population and changing socio-economic ... medicine in Asia. “We are excited to be a ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 In a ... March 17th, Governor Chris Christie is championing effective drug ... disorders.New Jersey is scrambling to recover funds to stabilize ... best care for victims of drug and alcohol addiction. ... to those plagued by substance use disorders in New ...
(Date:3/30/2015)... This report studies the global tumor ... to 2019. , Based on the type of ... into four major segments, namely radio-frequency, microwave, cryoablation ... and laser ablation) segments. Moreover, based on type ... classified into three segments, namely, interventional radiology, surgery ...
(Date:3/30/2015)... 2015 Tel-Aviv – March 30, 2015 ... announced the closing of $12.5 million in new financing ... Viola Group. The funding will further GlassesUSA's aggressive business ... in the growing global market of online eyewear, both ... by CEO Daniel Rothman, COO Eldad Rothman, and CTO ...
Breaking Medicine News(10 mins):Health News:World’s First Medical Intelligent Band was Featured on NewsWatch Television on January 30, 2015 2Health News:Innovaacom Expands Services and Medical Education Programs into Asia 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 3Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3
... easy access to alcohol-based handrubs can improve hygiene in ... Access journal Critical Care suggests. ,Good ... the spread of infections within hospitals. Alcohol-based handrubs are ... amongst hospital staff remains low. ,One of ...
... improved after one month on cholesterol-lowering drugs called statins ... to research that will be presented at the ... April 28 May 5, 2007. ,The ... of having a stroke or transient ischemic attack, or ...
... supply of stem cells that can repair the most severe ... These reservists normally lie around and do nothing, but ... jump into action. A report on the discovery will appear ... ,These stem cells act like the Army Reserves of ...
... tower and research at the Baltimore institution Johns Hopkins ... Hopkins Medicine from His Highness Sheikh Khalifa bin ... Emirates (UAE). Most of the gift, made in honor ... Al Nahyan, will support construction of The Johns Hopkins ...
... radio or the cell phone on the car seat next to ... turn up the dial or take a call while maneuvering ... for young drivers with Attention Deficit/Hyperactivity Disorder (ADHD). ... more likely to have a car accident than non-ADHD drivers. Daniel ...
... their first televised debate -- held at the Ronald ... -- fielded questions about their views on abortion rights, ... reports. ,The 90-minute debate included Sens. ... York City Mayor Rudolph Giuliani; former Virginia Gov. James ...
Cached Medicine News:Health News:When Smell Cells Fail They Call In Stem Cell Reserves 2Health News:Johns Hopkins Medicine Honors U.A.E. Sheikh Zayed Bin Sultan Al Nahyan 2Health News:Johns Hopkins Medicine Honors U.A.E. Sheikh Zayed Bin Sultan Al Nahyan 3Health News:Researchers To Test Whether ADHD Medication Helps Young Adults While Driving 2Health News:Republican Presidential Candidates Discuss Abortion, Stem Cells as Part of First Debate 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
Medicine Products: